

We are IntechOpen, the world's leading publisher of Open Access books Built by scientists, for scientists

4,800

Open access books available

122,000

International authors and editors

135M

Downloads

Our authors are among the

154

Countries delivered to

TOP 1%

most cited scientists

12.2%

Contributors from top 500 universities



WEB OF SCIENCE™

Selection of our books indexed in the Book Citation Index
in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?
Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected.

For more information visit www.intechopen.com



Synthesis and Anticancer Evaluation of Benzenesulfonamide Derivatives

Dattatraya Navnath Pansare and Rohini Narayan Shelke

Abstract

A highly efficient protocol was developed for the synthesis of 3-(indoline-1-carbonyl)-N-(substituted) benzene sulfonamide analogs with excellent yields. The new 3-(indoline-1-carbonyl)-N-(substituted) benzene sulfonamide derivatives (4a-g and 5a-g) were evaluated *in vitro* anticancer activity against a series of different cell lines like A549 (lung cancer cell), HeLa (cervical), MCF-7 (breast cancer cell) and Du-145 (prostate cancer cell) respectively. The results of the anticancer activity data revealed that most of the tested compounds showed IC₅₀ values from 1.98 to 9.12 μM in different cell lines. Compounds 4b, 4d, 5d, and 5g were the most potent, with IC₅₀ values ranging from 1.98 to 2.72 μM in different cell lines.

Keywords: indoline, sulfonamide, anticancer

1. Introduction

Antibiotic resistant bacteria are rapidly emerging worldwide [1]. The various biological active heterocyclic compounds, the indole derivatives are the key structural feature commonly found in natural products [2, 3] and bioactive molecules, such as tryptophan [4], tryptamine [5], and auxin [6]. Furthermore, it has been reported that sharing of the indole 3-carbon in the formation of spiroindoline derivatives highly enhances biological activity [7]. Moreover, some of the compounds containing benzenesulfonamide moiety also show broad spectrum biological properties such as elastase inhibitors [8], carbonic anhydrase inhibitors [9], clostridium histolyticum collagenase inhibitors [10] as well as herbicides and plant growth regulators [11]. Sulfonamides are common motifs in many drugs and medicinal compounds and play an important role in their bioactivity since the development of sulfa antibiotics in the 1930s [12]. Common drugs such as glibenclamide [13], sultiame [14], and COX-II inhibitors Piroxicam [15], Ampiroxicam [16], and Celecoxib [17] containing a sulfonyl moiety, which displays potential activity across a variety of biological targets. The sulfonamides are organic sulfur compounds which have attracted the attention for their better pharmacological activity [18–20]. It is interesting to note that the sulfonamide containing moiety is known to have some biological and pharmaceutical properties, such as, antitumor, antibacterial, thrombin inhibition, and antifungal activities [21–23].

In view of the above considerations, in continuation of our previous work on triazoles, pyrimidine, thiazoles and thiazolidinones of pharmaceutical interest [24–30] we report here on the synthesis and anticancer activity of new 3-(indoline-1-carbonyl)-N-(substituted) benzene sulfonamide analogs.

2. Results and discussion

2.1 Chemistry

The aim of this work was to design and synthesize a novel series of benzenesulfonamide incorporating biologically active indoline moieties to evaluate their anticancer activity. We have synthesized new derivatives containing sulfonamide linkage in frame work. The synthetic methods adopted for the preparation of the N-(substituted phenyl)-3-(indoline-1-carbonyl)benzenesulfonamide derivatives (**5a-g**) in **Figure 1**. We herein report the synthesis of new substituted sulfonamide derivatives with the aim of investigating their anticancer activity (**Table 2**). The synthetic methods adopted for the preparation of the title compounds (**5a-g**) are presented below. We have tried to develop simplified reaction conditions for all the steps by avoiding costly reagents, tedious purifications and longer reactions times, we have screened peptide coupling condition in **Table 1** to obtain better yield, good purity, shorter reaction time, avoiding costly reagents and mainly reproducibility of yields.

For synthesis of compound **2** was done by using **1** treated with sulfonyl chloride at 0°C in DCM for 30 min and at room temperature for 1 h. The reaction mixture was evaporated under reduced pressure and the obtained gummy material was washed with excess of n-hexane. The material was crystallized using 20% ethyl acetate: n-hexane mixture, no purification was required and the pure compound is obtained as yellow solid. This was used further used for sulfonamide reaction.




Figure 1.

Synthesis of N-(substituted phenyl)-3-(indoline-1-carbonyl)benzenesulfonamide. Reagents and conditions: (a) sulfonyl chloride, dichloromethane (DCM) 0°C-rt; (b) substituted amine, pyridine, DCM, 0°C-rt; (c) lithium hydroxide (LiOH), tetrahydrofuran (THF), water (H₂O), rt.; (d) indoline, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDCI), diisopropylethylamine (DIPEA), DCM, rt.

| Sr. no. | Coupling reagent | Base | Solvent | Time (h) | Yield (%) |
|---------|--------------------|--------------------|---------|----------|-----------|
| 1. | HATU (1.1 equiv.) | TEA (1.2 equiv.) | DMF | 14 | 57 |
| 2. | HATU (1.1 equiv.) | DIPEA (1.2 equiv.) | DMF | 14 | 55 |
| 3. | PyBOP (1.1 equiv.) | TEA (1.2 equiv.) | THF | 14 | 45 |
| 4. | PyBOP (1.1 equiv.) | DIPEA (1.2 equiv.) | THF | 14 | 50 |
| 5. | EDCI (1.5 equiv.) | TEA (2.5 equiv.) | DMF | 14 | 62 |
| 6. | HOBt (1.5 equiv.) | DIPEA (2.5 equiv.) | DMF | 14 | 72 |
| | EDCI (1.5 equiv.) | | | | |
| 7. | HOBt (1.5 equiv.) | TEA (4 equiv.) | DMF | 14 | 78 |
| | EDCI (1.5 equiv.) | | | | |
| 8. | HOBt (1.5 equiv.) | DIPEA (4 equiv.) | DMF | 14 | 67 |
| 9. | T3P (1.2 equiv.) | TEA (2.5 equiv.) | DCM | 10 | 50 |
| 10. | T3P (1.2 equiv.) | DIPEA (2.5 equiv.) | DCM | 10 | 60 |
| 11. | EDCI (1.5 equiv.) | DIPEA (2.5 equiv.) | DCM | 10 | 95 |

Acid (1 equiv.) and indoline (1.2 equiv.)

Table 1.
 Optimization of peptide coupling reaction (5a-g).

For the synthesis of compounds from **3a-g** by sulfonamide coupling, different substituted amines were coupled with **2** in presence of pyridine as base and DCM as solvent at room temperature for 4 h. The reaction mass was treated with cold 2N aqueous HCl and stirred for 30 min., the solid precipitates out in most of cases which was filtered and washed with cold diethyl ether and cold pentane, all the intermediates obtained were white solids. For intermediates **3a-g** the reaction yield was 85–95%.

For synthesis of **4a-4g** requires hydrolysis of **3a-g** using lithium hydroxide, tetrahydrofuran and water at room temperature for 10 h. Work up of reactions were modified, and wash in basic conditions and later acidifying it to get desired product as white solids with required purity. The acids obtained were in pure state so that it can be directly used for next amide coupling with indoline. All reaction intermediates **4a-g** yield up to 80–85%.

For synthesis of **5a-g** we have done series of screenings by varying different coupling reagents, different bases, solvents and time. We have varied the equivalents of reagents and bases used to get better yield and purity by avoiding column purifications. The results of screenings are explained in **Table 1**. In entry 1 and 2 we have used 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate (HATU) as coupling reagent and DMF as solvent we have varied bases triethylamine and diisopropylethylamine after 14 h we got product 57 and 55% respectively. In entries 3 and 4 we have used benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate (PyBOP) as coupling reagent and THF as solvent and TEA and DIPEA as base to obtain yields 45 and 50% respectively. In entries 5, 6, 7, and 8 we have used the EDCI and hydroxybenzotriazole (HOBt) as coupling reagents with DMF as solvent along with TEA and DIPEA as base in entries 5 and 6 we have used 2.5 equiv. of base and in entries 7 and 8 we have increased base as 4 equiv. for 14 h. The yields obtained are 62, 72, 78, and 67% respectively. Same results like entry 1 and 2 are obtained in entry 9 and 10 when we used propylphosphonic anhydride (T3P) as coupling reagent and TEA and DIPEA as bases in DCM to get 50 and 60% yield respectively. In entry 11 it was observed that when EDCI (1.5 equiv.) when used along with DIPEA (2.5 equiv.) in DCM the yields was 95%, highlighted bold in **Table 1**. Work up requires extraction, and later on washing with 2N aqueous hydrochloric acid (HCl) to

obtain solid compounds. Which was washed with 5% DCM: hexane, cold diethyl ether and cold pentane gives the desired compounds in yield highest yields and with 95% and above purity for **5a-g**. We have not used HOBt in entry 11 and 90% yield obtain after 10 h only. The advantage of peptide coupling screenings are no need of column chromatography, no costly reagents required, no prep purification required. All obtained compounds are with 95% and above purity and are directly used for anticancer testing.

2.2 Biological evaluation: anticancer activity

The synthesized compounds were evaluated for their *in vitro* anticancer activity against human lung cancer cell line (A549), cervical (HeLa) cancer cell line, breast cancer cell line (MCF-7) and prostate cell line (DU-145) using 5-fluorouracil as reference drug [31].

5-Flourouracil is used for anal, breast, colorectal, esophageal, stomach, pancreatic and skin cancers mainly. The response parameter calculated was the IC₅₀ value, which corresponds to the concentration required for 50% inhibition of cell viability. The results are presented in **Table 2**, where all compounds exhibit moderate to good activity compared to 5-fluorouracil as positive control. In the case of the human lung cancer cell line (A549) compounds **4a**, **4b**, **4d**, **4f**, **5d**, and **5g** were the most potent, with IC₅₀ values ranging from 1.98 to 2.82 μM. On the HeLa cell line the compounds which showed potent activity were **4b**, **4d**, **5d**, and **5g** (IC₅₀ = 1.99–2.92 μM). In case of the MCF-7 breast cancer cell line, the potent compounds were **4d**, **5d**, and **5g** with IC₅₀ activity of 2.12–2.52 μM. Lower activity was observed for the synthesized compounds on the Du-145 prostate cancer cell line, where the most potent candidates were compounds **5g** with IC₅₀ activity in the range of 2.12 μM. Generally, the lung

| Compound | A549 (lung cancer cell) | HeLa (cervical cancer cell) | MCF-7 (breast cancer cell) | Du-145 (prostate cancer cell) |
|----------|-------------------------|-----------------------------|----------------------------|-------------------------------|
| 4a | 1.98 ± 0.12 | 3.83 ± 0.16 | 3.52 ± 0.06 | 3.86 ± 0.16 |
| 4b | 2.81 ± 0.13 | 2.92 ± 0.08 | 2.32 ± 0.22 | 3.82 ± 0.12 |
| 4c | 4.81 ± 0.12 | 6.32 ± 0.04 | 4.32 ± 0.06 | 3.73 ± 0.12 |
| 4d | 2.82 ± 0.11 | 1.99 ± 0.22 | 2.36 ± 0.12 | 3.52 ± 0.11 |
| 4e | 3.86 ± 0.08 | 4.38 ± 0.06 | 3.63 ± 0.12 | 6.52 ± 0.22 |
| 4f | 2.72 ± 0.11 | 3.87 ± 0.08 | 4.12 ± 0.06 | 3.86 ± 0.22 |
| 4g | 3.14 ± 0.14 | 3.98 ± 0.12 | 4.86 ± 0.11 | 4.57 ± 0.11 |
| 5a | 8.48 ± 0.14 | 9.12 ± 0.08 | 7.82 ± 0.08 | 9.12 ± 0.06 |
| 5b | 3.82 ± 0.08 | 4.13 ± 0.12 | 3.13 ± 0.11 | 3.52 ± 0.08 |
| 5c | 4.13 ± 0.12 | 5.16 ± 0.08 | 6.12 ± 0.12 | 4.52 ± 0.11 |
| 5d | 2.06 ± 0.12 | 2.12 ± 0.08 | 2.52 ± 0.16 | 5.12 ± 0.08 |
| 5e | 2.52 ± 0.11 | 3.52 ± 0.11 | 4.48 ± 0.08 | 4.08 ± 0.11 |
| 5f | 4.48 ± 0.08 | 4.98 ± 0.11 | 5.17 ± 0.22 | 5.18 ± 0.18 |
| 5g | 2.73 ± 0.08 | 2.12 ± 0.12 | 2.12 ± 0.08 | 2.12 ± 0.04 |
| 5-FU | 1.61 ± 0.12 | 1.72 ± 0.18 | 1.81 ± 0.10 | 1.89 ± 0.12 |

Table 2.

In vitro anticancer screening of the synthesized compounds against four cell lines, data are expressed as IC₅₀ (μM) SD (n = 3).

(A549) and cervical (HeLa) cancer cell lines were the most sensitive to the synthesized compounds. With regard to broad spectrum anticancer activity, close examination of the data presented in **Table 2**, reveals that compounds **4b**, **4d**, and **5g** were the most active, showing effectiveness toward the four cell lines. The structure activity relationship (SAR) can be explained on the basis of substitutions on both the aromatic rings less hindered substitution like methyl and ethyl on ortho and para position of rings increases the anticancer activity in all four cell lines, interestingly ortho trifluoromethyl and indoline group decreases the anticancer activity and despite steric hindrance **4b**, **4d**, **5d**, and **5g** shows promising activity because of electron donating tendency. Most of the compounds show promising anticancer activity with electron donating groups on the ring than electron withdrawing groups.

2.3 General experimental procedure for the synthesis of N-(substituted phenyl)-3-(indoline-1-carbonyl)benzenesulfonamide (5a-g)

2.3.1 Step-1: preparation of ethyl 3-(chlorosulfonyl)benzoate (2)

To a stirred solution of ethyl benzoate (10 g, 67 mmol) in DCM (25 mL). RM was cooled to 0°C and chloro sulfonic acid (9 g, 73 mmol) was added drop wise and stirred for 1 h at same temperature followed by stirring at room temperature for 1 h. After completion of reaction, evaporate reaction mixture under reduced pressure and obtained gummy material is washed with excess of hexane and it is crystalized from 20% ethyl acetate: hexane mixture to obtain white solid as ethyl 3-(chlorosulfonyl)benzoate (**2**) which is used further for sulfonamide coupling reaction. Yield 54 g (81%).

2.3.2 Step-2: preparation of ethyl 3-(N-(o-tolyl)sulfamoyl)benzoate (3a-g)

To a stirred solution of ethyl 3-(chlorosulfonyl)benzoate (**2**) (3 g, 10.1 mmol) in DCM (5 ml) was added pyridine (5 ml) the mixture was stirred at room temperature for 10 min. RM was cooled to 0°C and 2-methyl aniline (1.6 g, 15.16 mmol) was added drop wise followed by stirring at room temperature for 3 h. The reaction was monitored by TLC and LCMS, after completion of reaction poured reaction mass on cold 2N aqueous HCl (10 ml) and stirred RM it for 30 min. Precipitation formed in RM. Filtered the obtained solid and wash it with excess of water and cold diethyl ether (10 ml) and cold pentane (10 ml) to obtain ethyl 3-(N-(o-tolyl)sulfamoyl)benzoate **2** as white solid. Yield 2.8 g (90%).

2.3.3 Step-3: preparation of 3-(N-(o-tolyl)sulfamoyl)benzoic acid (4a-g)

To a stirred solution of ethyl 3-(N-(o-tolyl)sulfamoyl)benzoate (**3a-g**) (2 g, 5.40 mmol) in THF (10 ml) added water (2 ml), and lithium hydroxide (0.377 g, 18.2 mmol) and stirred reaction mixture for 4 h. Progress reaction was monitored by TLC and LCMS. After the completion of reaction evaporate reaction mixture under reduced pressure to obtain gummy material. Added 10 ml of water in it and extracted it with diethyl ether (10 ml). Collected aqueous layer and adjust its pH to 4 by using 6N aqueous HCl. Precipitation occurs stirred it for 30 min. Filtered the obtained solid and wash it with excess of water, cold diethyl ether (10 ml) and cold pentane (10 ml) to obtain desired 3-(N-(o-tolyl)sulfamoyl)benzoic acid **4a** as white solids. Yield 1.6 g (90%).

2.3.4 Step-4: *N*-(substituted phenyl)-3-(indoline-1-carbonyl)benzenesulfonamide (5a-g)

The compound 3-(*N*-(*o*-tolyl)sulfamoyl)benzoic acid **4a-g** (0.2 g, 0.65 mmol) was treated with EDCI (0.188 g, 0.98 mmol), DIPEA (0.34 ml, 1.96 mmol) in DCM (10 ml). Then added 2,4-dimethyl aniline (0.238 g, 1.96 mmol) and stirred RM at room temperature for 4 h. The reaction was monitored by TLC. Added 10 ml of cold water and stirred for 10 min, then extracted it with 10 ml of DCM. Collected organic layer wash it with 1N aqueous HCl and washed with brine (10 ml). To evaporate the organic layer to obtained the compound with 90% purity (**5a-g**). Purification done by washing with 5:95% of DCM: hexane. Obtained solid washed with cold diethyl ether (20 ml) and cold pentane (20 ml) to obtain compounds (**5a-g**). *N*-(2,4-dimethylphenyl)-3-(*N*-(*o*-tolyl)sulfamoyl)benzamide (**5a**): (0.240 g, 90%) as white solid, LC-MS *m/z* (%): 395 (M + H). ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.05 (s, 1H), 9.70 (s, 1H), 8.26 (s, 1H), 8.22 (d, *J* = 7.6 Hz, 1H), 7.81 (d, *J* = 8 Hz, 1H), 7.7 (d, *J* = 8 Hz, 1H), 7.18–7.13 (m, 2H), 7.1–7.08 (m, 3H), 7.01 (d, *J* = 8.4 Hz, 1H), 6.95–6.92 (m, 1H), 2.28 (s, 3H), 2.15 (s, 3H), 2.02 (s, 3H). HPLC-98.25% RT-5.68 min. ¹³C NMR (CDCl₃, 100 MHz): 17.65, 17.79, 20.54, 126.09, 126.38, 126.40, 126.43, 126.58, 129.23, 129.42, 130.82, 130.89, 131.38, 133.42, 133.62, 134.27, 134.65, 135.40, 135.41, 135.45, 141.09, 163.93.

3. Conclusion

An effective method was developed which provided an easy access to a new series *N*-(substituted phenyl)-3-(indoline-1-carbonyl)benzenesulfonamide (**5a-g**) analogs. The mild reaction conditions, good to excellent yields, ease of workup and easily available substrates make the reactions attractive for the preparation of compounds. The compounds (**4b**, **4d**, **5d**, and **5g**) show potent anticancer activity in all the four cell lines tested. The compounds are easy, simple and reproducible to synthesize in normal conditions and no additional conditions or expensive chemicals are required for the reaction. The cell-lines with maximum IC₅₀ values are the important in the study.

Acknowledgements

The authors are thankful to the Head, Department of Chemistry, Deogiri college, Aurangabad for the laboratory facility.

IntechOpen

IntechOpen

Author details

Dattatraya Navnath Pansare* and Rohini Narayan Shelke
Department of Chemistry, Deogiri College, Aurangabad, MS, India

*Address all correspondence to: dattatraya.pansare7@gmail.com

IntechOpen

© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/3.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 

References

- [1] Walsh CT, Wencewicz TA. Prospects for new antibiotics: A molecule-centered perspective. *The Journal of Antibiotics*. 2013;**67**:7. DOI: 10.1038/ja.2013.49
- [2] Alvarez M, Salas M, Joule JA. Marine, nitrogen-containing heterocyclic natural products—Structures and syntheses of compounds containing indole units. *Heterocycles*. 1991;**32**(7):1391. DOI: 10.3987/rev-91-429
- [3] Ruiz-Sanchis P, Savina SA, Albericio F, Alvarez M. Structure, bioactivity and synthesis of natural products with hexahydropyrrolo[2,3-b]indole. *Chemistry—A European Journal*. 2011;**17**(5):1388. DOI: 10.1002/chem.201001451
- [4] Mantle PG. The role of tryptophan as a biosynthetic precursor of indole-diterpenoid fungal metabolites: Continuing a debate. *Phytochemistry*. 2009;**70**(1):7. DOI: 10.1016/j.phytochem.2008.11.004
- [5] Jones RSG. Tryptamine: A neuromodulator or neurotransmitter in mammalian brain. *Progress in Neurobiology*. 1982;**19**(1-2):117. DOI: 10.1016/0301-0082(82)90023-5
- [6] Folkes LK, Wardman P. Oxidative activation of indole-3-acetic acids to cytotoxic species—A potential new role for plant auxins in cancer therapy. *Biochemical Pharmacology*; **61**(2):129. DOI: 10.1016/S0006-2952(00)00498-6
- [7] Abdel-Rahman AH, Keshk EM, Hanna MA, El-Bady SM. *Bioorganic & Medicinal Chemistry*. 2004;**12**(9):2483. DOI: 10.1016/j.bmc.2003.10.063
- [8] Scozzafava A, Owa T, Mastrolorenzo A, Supuran CT. Anticancer and antiviral sulfonamides. *Current Medicinal Chemistry*. 2003;**10**:925. DOI: 10.2174/0929867033457647
- [9] Scozzafava A, Briganti F, Ilies MA, Supuran CT. Carbonic anhydrase inhibitors: Synthesis of membrane-impermeant low molecular weight sulfonamides possessing in vivo selectivity for the membrane-bound versus cytosolic isozymes. *Journal of Medicinal Chemistry*. 2000;**43**:292. DOI: 10.1021/jm990479+
- [10] Scozzafava A, Supuran CT. Protease inhibitors. Part 8: Synthesis of potent *Clostridium histolyticum* collagenase inhibitors incorporating sulfonylated L-alanine hydroxamate moieties. *Bioorganic & Medicinal Chemistry*. 2000;**8**:637. DOI: 10.1016/S0968-0896(99)00316-8
- [11] Levitt G. Agricultural sulfonamides. U. S. Patent No. 4, 383, 113; 1983
- [12] Drews J. Drug discovery: A historical perspective. *Science*. 2000;**287**:1960. DOI: 10.1126/science.287.5460.1960
- [13] Wells GJ, Tao M, Josef KA, Bihovsky R. 1,2-Benzothiazine 1,1-dioxide P(2)-P(3) peptide mimetic aldehyde calpain I inhibitors. *Journal of Medicinal Chemistry*. 2001;**44**:3488. DOI: 10.1021/jm010178b
- [14] Brooke EW, Davies SG, Mulvaney WA. Synthesis and in vitro evaluation of novel small molecule inhibitors of bacterial arylamine N-acetyltransferases (NATs). *Bioorganic & Medicinal Chemistry Letters*. 2003;**13**:2527. DOI: 10.1016/S0960-894X(03)00484-0
- [15] Bihovsky R, Tao M, Mallamo JP, Wells GJ. 1,2-Benzothiazine 1,1-dioxide alpha-ketoamide analogues as potent calpain I inhibitors. *Bioorganic & Medicinal Chemistry Letters*. 2004;**14**:1035. DOI: 10.1016/j.bmcl.2003.11.037

- [16] Zia-ur-Rehman M, Choudary JA, Ahmad S, Siddiqui HL. Synthesis of potential biologically active 1,2-benzothiazin-3-yl-quinazolin-4(3H)-ones. *Chemical & Pharmaceutical Bulletin*. 2006;**54**:1175
- [17] Hendricks RT, Spencer SR, Blake JF. 3-Hydroxyisoquinolines as inhibitors of HCV NS5b RNA-dependent RNA polymerase. *Bioorganic & Medicinal Chemistry Letters*. 2009;**19**:410. DOI: 10.1016/j.bmcl.2008.11.060
- [18] Kwon Y, Song J, Lee H, Kim EY, Lee K, Lee SK, et al. Design, synthesis, and biological activity of sulfonamide analogues of antofine and cryptopleurine as potent and orally active antitumor agents. *Journal of Medicinal Chemistry*. 2015;**58**:7749. DOI: 10.1021/acs.jmedchem.5b00764
- [19] Sławinski J, Szafranski K, Vullo D, Supuran CT. Carbonic anhydrase inhibitors. Synthesis of heterocyclic 4-substituted pyridine-3-sulfonamide derivatives and their inhibition of the human cytosolic isozymes I and II and transmembrane tumor-associated isozymes IX and XII. *European Journal of Medicinal Chemistry*. 2013;**69**:701. DOI: 10.1016/j.ejmech.2013.09.027
- [20] Mirjafary Z, Ahmadi L, Moradi M, Saeidian H. A copper(II)-thioamide combination as a robust heterogeneous catalytic system for green synthesis of 1,4-disubstituted-1,2,3-triazoles under click conditions. *RSC Advances*. 2015;**5**:78038. DOI: 10.1039/C5RA16581D
- [21] Pingaew R, Prachayasittikul V, Mandi P, Nantasenamat C, Prachayasittikul S, Ruchirawat S, et al. Synthesis and molecular docking of 1,2,3-triazole-based sulfonamides as aromatase inhibitors. *Bioorganic & Medicinal Chemistry*. 2015;**23**:3472. DOI: 10.1016/j.bmc.2015.04.036
- [22] Wang XL, Wan K, Zhou CH. Synthesis of novel sulfanilamide-derived 1,2,3-triazoles and their evaluation for antibacterial and antifungal activities. *European Journal of Medicinal Chemistry*. 2010;**45**:4631. DOI: 10.1016/j.ejmech.2010.07.031
- [23] Zhang Z, Jeyakkumar P, Kumar KV, Zhou CH. Synthesis of novel sulfonamide azoles via C-N cleavage of sulfonamides by azole ring and relational antimicrobial study. *New Journal of Chemistry*. 2015;**39**:5776. DOI: 10.1039/C4NJ01932F
- [24] Pansare DN, Shelke RN, Pawar CD. A facile synthesis of (Z)-2-((5-(4-chlorobenzylidene)-4-oxo-4,5-dihydrothiazol-2-yl)amino) substituted acid using microwave irradiation and conventional method. *Letters in Organic Chemistry*. 2017;**14**(7):517. DOI: 10.2174/1570178614666170524142722
- [25] Pansare DN, Shelke RN, Shinde DB. A facial synthesis and anticancer activity of (Z)-2-((5-(4-nitrobenzylidene)-4-oxo-4,5-dihydrothiazol-2-yl)amino) substituted acid. *Journal of Heterocyclic Chemistry*. 2017;**54**(6):3077. DOI: 10.1002/jhet.2919
- [26] Pansare DN, Shinde DB. A facile synthesis of novel series (Z)-2-((4-oxo-5-(thiophen-2-yl methylene)-4,5-dihydrothiazol-2-yl)amino) substituted acid. *Journal of Saudi Chemical Society*. 2017;**21**:434. DOI: 10.1016/j.jscs.2015.10.005
- [27] Pawar CD, Chavan SL, Pawar UD, Pansare DN, Deshmukh SV, Shinde DB. Synthesis, anti-proliferative activity, SAR and kinase inhibition studies of thiazol-2-yl-substituted sulfonamide derivatives. *Journal of the Chinese Chemical Society*. 2018. DOI: 10.1002/jccs.201800312
- [28] Pawar CD, Pansare DN, Shinde DB. (Substituted)-benzo[b]

thiophene-4-carboxamide synthesis and anti-proliferative activity study. *Letters in Drug Design & Discovery*. 2018. DOI: 10.2174/1570180815666181004114125

[29] Pawar CD, Pansare DN, Shinde DB. Synthesis of new 3-(substituted phenyl)-N-(2-hydroxy-2-(substituted phenyl)ethyl)-N-methylthiophene-2-sulfonamide derivatives as antiproliferative agents. *European Journal of Chemistry*. 2018;**9**(1):13. DOI: 10.5155/eurjchem.9.1.13-21.1669

[30] Pawar CD, Pansare DN, Shinde DB. Synthesis and antiproliferative activity of 3-(substituted)-4,5,6,7-tetrahydro-6-(substituted)-1H-pyrazolo[3,4-c]pyridine derivatives. *European Journal of Chemistry*. 2017;**8**(4):400. DOI: 10.5155/eurjchem.8.4.400-409.1645

[31] Skehan P, Storeng R, Scudiero D, Monks A, McMohan J, Vistica D, et al. New colorimetric cytotoxicity assay for anticancer-drug screening. *Journal of the National Cancer Institute*. 1990;**82**:1107